Research Atlas · source screening

Telavancin

An attributable first-pass index of PubMed records whose titles name this governed identity. Records are sorted by publication date, not by evidence strength. Inclusion does not establish efficacy, safety, or a clinical indication.

Title-search results

258

Shown with stable PMIDs

25

Search recorded

2026-09-26

Source: NCBI PubMed / MEDLINE · exact query: "Telavancin"[Title] · up to 25 recent title matches per identity. Each result links to its PubMed record.

1. In vivo tolerability of topical telavancin versus vancomycin in a murine ocular model.

   J Antimicrob Chemother · 2026 Jul 2 · PMID 42483981 · DOI 10.1093/jac/dkag250

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

2. In vitro persistence of clinical methicillin-resistant Staphylococcus aureus isolates from bone and joint infections after exposure to daptomycin, telavancin, and vancomycin.

   Microbiol Spectr · 2025 Dec 2 · PMID 41128537 · DOI 10.1128/spectrum.01576-25

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

3. Population pharmacokinetic analyses for telavancin using data from healthy subjects and patients with infections.

   Antimicrob Agents Chemother · 2025 Jul 2 · PMID 40503947 · DOI 10.1128/aac.01382-24

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

4. Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia.

   Cureus · 2025 Feb · PMID 40151684 · DOI 10.7759/cureus.79588

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

5. Telavancin.

   Journal not recorded · 2006 · PMID 29999745

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

6. Telavancin and Cardiac Surgery: Balancing Antimicrobial Efficacy With Coagulation Challenges.

   J Cardiothorac Vasc Anesth · 2024 Dec · PMID 39426857 · DOI 10.1053/j.jvca.2024.09.147

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

7. Rapid in vitro activity of telavancin against Bacillus anthracis and in vivo protection against inhalation anthrax infection in the rabbit model.

   Antimicrob Agents Chemother · 2024 Jul 9 · PMID 38888319 · DOI 10.1128/aac.00112-24

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

8. The efficacy of telavancin in comparison with linezolid on endotracheal tube biofilm in pigs with methicillin-resistant Staphylococcus aureus pneumonia.

   Int J Antimicrob Agents · 2024 Feb · PMID 38072170 · DOI 10.1016/j.ijantimicag.2023.107052

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

9. Pharmacokinetics and safety of a single dose of telavancin in pediatric subjects 2-17 years of age.

   Antimicrob Agents Chemother · 2023 Nov 15 · PMID 37815398 · DOI 10.1128/aac.00987-23

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

10. National surveillance of antimicrobial susceptibilities to ceftaroline, dalbavancin, telavancin, tedizolid, eravacycline, omadacycline, and other comparator antibiotics, and genetic characteristics of bacteremic Staphylococcus aureus isolates in adults: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) program in 2020.

    Int J Antimicrob Agents · 2023 Apr · PMID 36758774 · DOI 10.1016/j.ijantimicag.2023.106745

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

11. Evaluation of a Capped Dosing Telavancin Regimen Compared to Standard Dosing at a Large Community Teaching Hospital.

    Antimicrob Agents Chemother · 2022 Jan 18 · PMID 34662182 · DOI 10.1128/AAC.01603-21

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

12. Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis.

    J Antimicrob Chemother · 2021 Dec 24 · PMID 34613416 · DOI 10.1093/jac/dkab370

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

13. Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™).

    Drugs Real World Outcomes · 2021 Dec · PMID 34041706 · DOI 10.1007/s40801-021-00255-6

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

14. Erratum for Crandon et al., "Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model".

    Antimicrob Agents Chemother · 2021 Nov 17 · PMID 34787468 · DOI 10.1128/AAC.01878-21

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

15. National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive Streptococcus pneumoniae isolates in adults: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) programme in 2017-2020.

    J Glob Antimicrob Resist · 2021 Sep · PMID 34289409 · DOI 10.1016/j.jgar.2021.07.005

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

16. Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment.

    Eur J Clin Pharmacol · 2021 Jul · PMID 33447912 · DOI 10.1007/s00228-020-03072-y

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

17. Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A∗32:01-positive vancomycin-induced DRESS sharing an HLA class II haplotype.

    J Allergy Clin Immunol · 2021 Jan · PMID 32439433 · DOI 10.1016/j.jaci.2020.04.056

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

18. Efficacy of Telavancin in Comparison to Linezolid in a Porcine Model of Severe Methicillin-Resistant Staphylococcus aureus Pneumonia.

    Antimicrob Agents Chemother · 2020 Dec 16 · PMID 33046500 · DOI 10.1128/AAC.01009-20

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

19. Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review.

    Int J Antimicrob Agents · 2020 Sep · PMID 32629114 · DOI 10.1016/j.ijantimicag.2020.106072

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

20. Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™).

    Drugs Real World Outcomes · 2020 Sep · PMID 32372280 · DOI 10.1007/s40801-020-00191-x

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

21. Antimicrobial Activity of Telavancin Tested In Vitro Against a Global Collection of Gram-Positive Pathogens, Including Multidrug-Resistant Isolates (2015-2017).

    Microb Drug Resist · 2020 Aug · PMID 32049591 · DOI 10.1089/mdr.2019.0104

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

22. Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016.

    J Glob Antimicrob Resist · 2020 Mar · PMID 31325617 · DOI 10.1016/j.jgar.2019.07.007

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

23. Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.

    Antimicrob Agents Chemother · 2019 Dec 20 · PMID 31685468 · DOI 10.1128/AAC.01914-19

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

24. Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™).

    Drugs Real World Outcomes · 2019 Dec · PMID 31696440 · DOI 10.1007/s40801-019-00165-8

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

25. Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.

    Eur J Clin Microbiol Infect Dis · 2019 Dec · PMID 31446513 · DOI 10.1007/s10096-019-03683-z

    Source metadata only · evidence grade unassigned · scientific conclusions pending review